Richard A Rifkind

USPTO Granted Patents = 22 (Patent Applications = 2)

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 573(Granted Patents)

Company Filing History:

19 out of 512

Sloan-kettering Institute for Cancer Research

The Trustees of Columbia

patent

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1991-2011

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 7879865 - Treatment of cancer of the brain using histone deacetylase inhibitors (2011-02-01),

2. 7816499 - Antibodies that selectively bind HDAC9 (2010-10-19),

3. 7799803 - Hydroxamic acid compounds and methods of use thereof (2010-09-21),

4. 7345174 - Cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof (2008-03-18),

5. 7244604 - HDAC9 polypeptides and polynucleotides and uses thereof (2007-07-17),

6. 7199134 - Hydroxamic acid compounds and methods of use thereof (2007-04-03),

7. 7126001 - Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof (2006-10-24),

8. 7124068 - Crystal structure of a deacetylase and inhibitors thereof (2006-10-17),

9. 7063973 - HDAC9 polypeptides and polynucleotides and uses thereof (2006-06-20),

10. RE38506 - Potent inducers of terminal differentiation and methods of use thereof (2004-04-20),

11. 6511990 - Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof (2003-01-28),

12. 6087367 - Potent inducers of terminal differentiation and methods of use thereof (2000-07-11),

13. 5932616 - Potent inducers of terminal differentiation and methods of use thereof (1999-08-03),

14. 5840960 - Potent inducers of terminal differentiation and method of use thereof (1998-11-24),

15. 5773474 - Potent inducers of terminal differentiation and method of use thereof (1998-06-30),

Title: Exploring the Innovative Work of Inventor Richard A Rifkind

Introduction:

Richard A Rifkind, a prolific inventor based in New York, NY (US), has made significant contributions in the field of medical research and treatment. With an impressive portfolio of 22 patents, his groundbreaking innovations have revolutionized the treatment of diseases, particularly in the realm of neurodegenerative disorders.

Latest Patents:

1. Treatment of cancer of the brain using histone deacetylase inhibitors: In this patent, Rifkind introduces a method for treating diseases of the central nervous system by administering histone deacetylase inhibitors. This approach shows promise in combatting neurodegenerative diseases, including inherited ones like polyglutamine expansion diseases.

2. Antibodies that selectively bind HDAC9: Rifkind's invention encompasses purified antibodies that specifically target histone deacetylase polypeptides, highlighting his innovative approach to combating cellular substrates and promoting transcription repression activity.

Career Highlights:

Richard A Rifkind has been associated with prestigious institutions such as Sloan-Kettering Institute for Cancer Research and Columbia University in the City of New York. His work in these esteemed organizations has paved the way for groundbreaking discoveries in the field of medical research, particularly in the areas of cancer treatment and neurodegenerative disorders.

Collaborations:

During his illustrious career, Rifkind has collaborated with esteemed researchers and colleagues, including Paul A Marks and Ronald C Breslow. These collaborations have enriched his research endeavors and have led to the development of novel treatment modalities that have the potential to transform the landscape of medical science.

Conclusion:

Inventor Richard A Rifkind's dedication to advancing medical research and treatment modalities is truly commendable. His innovative patents and collaborations have significantly contributed to the understanding and treatment of complex diseases, offering hope to individuals battling neurodegenerative disorders and cancer. Richard A Rifkind's pioneering work continues to inspire future generations of inventors and researchers in the pursuit of improving human health and wellbeing.

This text is generated by artificial intelligence and may not be accurate.